Jyong Biotech's Strategic Vision for Plant-Derived Therapies
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
Source: Newsfilter
- Market Potential Analysis: CEO Fu-Feng Kuo highlighted that there are approximately 12.2 million benign prostatic hyperplasia (BPH) patients in the US, with about 35% in 'watchful waiting' and 9.1% discontinuing treatment due to side effects, indicating a significant market opportunity for Botreso® to address unmet medical needs.
- Clinical Data Support: The company has fortified its New Drug Application (NDA) with extensive data from two pivotal studies and two one-year open-label extension studies conducted in the US and Taiwan, confirming no emergent safety signals, which enhances Botreso®'s clinical profile and is expected to facilitate FDA approval.
- Strategic Collaboration Opportunities: The Company's Prostate Cancer Prevention (PCP) asset has completed a Phase II trial in Taiwan, demonstrating the safety profile required for lifelong preventative therapies, and is currently in discussions with major pharmaceutical companies for co-development and co-funding, further expanding market opportunities.
- Global Market Priority: CEO Kuo reaffirmed that the United States is the company's unequivocal first priority, as securing FDA approval not only provides access to premium drug pricing but also accelerates regulatory pathways in Brazil, Israel, and broader Asia, reflecting the company's strategic focus on global markets.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MENS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MENS
About MENS
Jyong Biotech Ltd is a Taiwan-based science-driven biotechnology company. The Company is mainly engaged in developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the United States (U.S.), the European Union (EU), and Asia. The Company has been developing a series of botanical drug candidates, including primary botanical drug candidate of MCS-2, another clinical-stage botanical drug candidate of PCP, and other preclinical-stage botanical drug candidates. MCS-2 is a new botanical drug candidate developed for treatment of benign prostate hyperplasia/lower urinary tract symptoms (BPH/LUTS). PCP is a new botanical drug candidate developed for the prevention of prostate cancer.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Jyong Biotech's Strategic Vision for Plant-Derived Therapies
- Market Potential Analysis: CEO Fu-Feng Kuo highlighted that there are approximately 12.2 million benign prostatic hyperplasia (BPH) patients in the US, with about 35% in 'watchful waiting' and 9.1% discontinuing treatment due to side effects, indicating a significant market opportunity for Botreso® to address unmet medical needs.
- Clinical Data Support: The company has fortified its New Drug Application (NDA) with extensive data from two pivotal studies and two one-year open-label extension studies conducted in the US and Taiwan, confirming no emergent safety signals, which enhances Botreso®'s clinical profile and is expected to facilitate FDA approval.
- Strategic Collaboration Opportunities: The Company's Prostate Cancer Prevention (PCP) asset has completed a Phase II trial in Taiwan, demonstrating the safety profile required for lifelong preventative therapies, and is currently in discussions with major pharmaceutical companies for co-development and co-funding, further expanding market opportunities.
- Global Market Priority: CEO Kuo reaffirmed that the United States is the company's unequivocal first priority, as securing FDA approval not only provides access to premium drug pricing but also accelerates regulatory pathways in Brazil, Israel, and broader Asia, reflecting the company's strategic focus on global markets.
See More
Jyong Biotech Releases Annual Report for 2025
- Annual Report Filing: Jyong Biotech filed its annual report on Form 20-F with the SEC on May 14, 2026, reflecting the company's ongoing development and compliance in the biotechnology sector.
- Financial Transparency: The company will provide access to the annual report on its investor relations website and the SEC's site, ensuring shareholders can easily obtain audited financial statements, thereby enhancing investor trust and transparency.
- Innovative Drug Development: Jyong Biotech focuses on developing plant-derived therapeutics aimed at treating urinary system diseases, showcasing its expertise and market potential in the biopharmaceutical field.
- Market Positioning: Since its inception in 2002, the company has built comprehensive drug development capabilities, aiming to meet health needs in the U.S., EU, and Asia, further solidifying its position in the global biotechnology industry.
See More
Jyong Biotech Advances Market Access Strategies for Plant-Based Drugs
- Successful Clinical Trials: Jyong Biotech's core product Botreso® has completed four Phase III clinical trials in the U.S. and Taiwan, demonstrating significant clinical efficacy and safety, which is expected to enhance market competitiveness and attract more investor interest.
- Safety Advantage: No serious adverse events were observed during the clinical trials for Botreso® and PCP, indicating superior long-term safety compared to existing synthetic drugs, potentially appealing to middle-aged and elderly male patients seeking safer treatment options.
- Massive Market Potential: Over 500 million men aged 50 and above globally seek treatment for Benign Prostatic Hyperplasia (BPH), with the BPH drug market projected to reach $9.8 billion by 2026, positioning Jyong Biotech's products to capture a significant share of this rapidly growing market.
- High Technological Barriers: Jyong Biotech has established a comprehensive technology platform to ensure quality control for botanical drugs, reducing the risk of generic competition and extending market exclusivity, thereby enhancing the company's strategic position in the biotech industry.
See More
Jyong Biotech Updates on MCS®-2 Clinical Progress
- World's First Plant-Based Drug: MCS®-2 is the only oral botanical new drug to complete global Phase III clinical trials for BPH, showcasing significant market potential to address the treatment needs of hundreds of millions of men.
- Extensive Clinical Trials: Four Phase III trials conducted in the U.S. and Taiwan involved 27 centers and over 200 urologists, ensuring data reliability and laying a strong foundation for future commercialization.
- Rigorous Scientific Validation: MCS®-2 adhered to FDA standards throughout all clinical phases, with no serious adverse events reported, indicating its safety for long-term use and enhancing market confidence.
- Global Patent Protection: The company holds a patent portfolio across the Americas, Asia, and Europe, ensuring the competitiveness of its core technology and enabling the development of multiple formulations to meet diverse patient needs.
See More
Jyong Biotech Reports Clinical Progress and Market Strategy
- Clinical Trial Success: Jyong Biotech completed the Phase II trial for MCS-8, enrolling over 700 high-risk subjects, with results showing a 27.3% reduction in prostate cancer incidence compared to placebo, establishing a strong foundation for the company's position in preventative medicine.
- Metabolic Health Improvement: The MCS-8 group exhibited significant reductions in total cholesterol (P = 0.036) over two years, alongside decreased triglycerides and LDL levels, and increased HDL, indicating potential for expanding indications to atherosclerosis and cardiovascular disease management.
- Safety Validation: The Phase II study reported no serious adverse events related to MCS-8, with no negative impacts on blood pressure or liver and kidney function, while stable LDH levels reinforced its long-term safety profile, boosting market confidence.
- Commercialization Strategy: The company signed non-binding Letters of Intent with pharmaceutical firms in South Korea and Vietnam to co-commercialize MCS-2, demonstrating its commitment to expanding in the rapidly growing Asian market to meet increasing demand for urological therapeutics.
See More
Jyong Biotech Achieves Milestone with MCS-8 Phase II Trial Success
- Clinical Trial Success: Jyong Biotech completed the Phase II trial for MCS-8, enrolling over 700 high-risk subjects, achieving a statistically significant 27.3% reduction in prostate cancer incidence compared to placebo, establishing a strong foundation for preventative medicine.
- Metabolic Health Improvement: The MCS-8 group exhibited a significant reduction in total cholesterol (P = 0.036) over two years, alongside decreased triglycerides and LDL levels, indicating the drug's potential dual-action capability in reducing cancer risk while enhancing metabolic health.
- Safety Validation: The Phase II study indicated no serious adverse events over two years, with no negative impacts on blood pressure or liver/kidney function, and stable LDH levels, reinforcing confidence in the drug's long-term safety profile for prophylactic use.
- Commercialization Strategy: The company has signed a non-binding Letter of Intent with a South Korean pharmaceutical firm and a Memorandum of Understanding with a Vietnamese distributor to co-commercialize MCS-2, demonstrating its commitment to expanding in the Asian market and unlocking potential commercial value.
See More
Jyong Biotech's Strategic Vision for Plant-Derived Therapies
- Market Potential Analysis: CEO Fu-Feng Kuo highlighted that there are approximately 12.2 million benign prostatic hyperplasia (BPH) patients in the US, with about 35% in 'watchful waiting' and 9.1% discontinuing treatment due to side effects, indicating a significant market opportunity for Botreso® to address unmet medical needs.
- Clinical Data Support: The company has fortified its New Drug Application (NDA) with extensive data from two pivotal studies and two one-year open-label extension studies conducted in the US and Taiwan, confirming no emergent safety signals, which enhances Botreso®'s clinical profile and is expected to facilitate FDA approval.
- Strategic Collaboration Opportunities: The Company's Prostate Cancer Prevention (PCP) asset has completed a Phase II trial in Taiwan, demonstrating the safety profile required for lifelong preventative therapies, and is currently in discussions with major pharmaceutical companies for co-development and co-funding, further expanding market opportunities.
- Global Market Priority: CEO Kuo reaffirmed that the United States is the company's unequivocal first priority, as securing FDA approval not only provides access to premium drug pricing but also accelerates regulatory pathways in Brazil, Israel, and broader Asia, reflecting the company's strategic focus on global markets.
See More
Jyong Biotech Releases Annual Report for 2025
- Annual Report Filing: Jyong Biotech filed its annual report on Form 20-F with the SEC on May 14, 2026, reflecting the company's ongoing development and compliance in the biotechnology sector.
- Financial Transparency: The company will provide access to the annual report on its investor relations website and the SEC's site, ensuring shareholders can easily obtain audited financial statements, thereby enhancing investor trust and transparency.
- Innovative Drug Development: Jyong Biotech focuses on developing plant-derived therapeutics aimed at treating urinary system diseases, showcasing its expertise and market potential in the biopharmaceutical field.
- Market Positioning: Since its inception in 2002, the company has built comprehensive drug development capabilities, aiming to meet health needs in the U.S., EU, and Asia, further solidifying its position in the global biotechnology industry.
See More
Jyong Biotech Advances Market Access Strategies for Plant-Based Drugs
- Successful Clinical Trials: Jyong Biotech's core product Botreso® has completed four Phase III clinical trials in the U.S. and Taiwan, demonstrating significant clinical efficacy and safety, which is expected to enhance market competitiveness and attract more investor interest.
- Safety Advantage: No serious adverse events were observed during the clinical trials for Botreso® and PCP, indicating superior long-term safety compared to existing synthetic drugs, potentially appealing to middle-aged and elderly male patients seeking safer treatment options.
- Massive Market Potential: Over 500 million men aged 50 and above globally seek treatment for Benign Prostatic Hyperplasia (BPH), with the BPH drug market projected to reach $9.8 billion by 2026, positioning Jyong Biotech's products to capture a significant share of this rapidly growing market.
- High Technological Barriers: Jyong Biotech has established a comprehensive technology platform to ensure quality control for botanical drugs, reducing the risk of generic competition and extending market exclusivity, thereby enhancing the company's strategic position in the biotech industry.
See More
Jyong Biotech Updates on MCS®-2 Clinical Progress
- World's First Plant-Based Drug: MCS®-2 is the only oral botanical new drug to complete global Phase III clinical trials for BPH, showcasing significant market potential to address the treatment needs of hundreds of millions of men.
- Extensive Clinical Trials: Four Phase III trials conducted in the U.S. and Taiwan involved 27 centers and over 200 urologists, ensuring data reliability and laying a strong foundation for future commercialization.
- Rigorous Scientific Validation: MCS®-2 adhered to FDA standards throughout all clinical phases, with no serious adverse events reported, indicating its safety for long-term use and enhancing market confidence.
- Global Patent Protection: The company holds a patent portfolio across the Americas, Asia, and Europe, ensuring the competitiveness of its core technology and enabling the development of multiple formulations to meet diverse patient needs.
See More
Jyong Biotech Reports Clinical Progress and Market Strategy
- Clinical Trial Success: Jyong Biotech completed the Phase II trial for MCS-8, enrolling over 700 high-risk subjects, with results showing a 27.3% reduction in prostate cancer incidence compared to placebo, establishing a strong foundation for the company's position in preventative medicine.
- Metabolic Health Improvement: The MCS-8 group exhibited significant reductions in total cholesterol (P = 0.036) over two years, alongside decreased triglycerides and LDL levels, and increased HDL, indicating potential for expanding indications to atherosclerosis and cardiovascular disease management.
- Safety Validation: The Phase II study reported no serious adverse events related to MCS-8, with no negative impacts on blood pressure or liver and kidney function, while stable LDH levels reinforced its long-term safety profile, boosting market confidence.
- Commercialization Strategy: The company signed non-binding Letters of Intent with pharmaceutical firms in South Korea and Vietnam to co-commercialize MCS-2, demonstrating its commitment to expanding in the rapidly growing Asian market to meet increasing demand for urological therapeutics.
See More
Jyong Biotech Achieves Milestone with MCS-8 Phase II Trial Success
- Clinical Trial Success: Jyong Biotech completed the Phase II trial for MCS-8, enrolling over 700 high-risk subjects, achieving a statistically significant 27.3% reduction in prostate cancer incidence compared to placebo, establishing a strong foundation for preventative medicine.
- Metabolic Health Improvement: The MCS-8 group exhibited a significant reduction in total cholesterol (P = 0.036) over two years, alongside decreased triglycerides and LDL levels, indicating the drug's potential dual-action capability in reducing cancer risk while enhancing metabolic health.
- Safety Validation: The Phase II study indicated no serious adverse events over two years, with no negative impacts on blood pressure or liver/kidney function, and stable LDH levels, reinforcing confidence in the drug's long-term safety profile for prophylactic use.
- Commercialization Strategy: The company has signed a non-binding Letter of Intent with a South Korean pharmaceutical firm and a Memorandum of Understanding with a Vietnamese distributor to co-commercialize MCS-2, demonstrating its commitment to expanding in the Asian market and unlocking potential commercial value.
See More
